Results 181 to 190 of about 990,536 (371)

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source

CEREBRAL N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE IN THE PROGNOSIS OF STABLE ANGINA DEPENDENT ON CHANGES OF URIC ACID

, 2016
В. К. Тащук, Mukhamed Vasek Obeid Al Salama, T. M. Amelina   +2 more
openalex   +2 more sources

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes

Vascular Health and Risk Management, 2010
Magnus Dencker1, Martin Stagmo2, Mozhgan Dorkhan31Unit of Clinical Physiology and Nuclear Medicine, Department of Clinical Sciences, 2Division of Cardiology, 3Division of Diabetes and Endocrinology, Malmö University Hospital, Malm&ouml ...
Magnus Dencker, Martin Stagmo, Mozhgan Dorkhan   +2 more
doaj  

Developmental roles of natriuretic peptides and their receptors. [PDF]

Cells Dev, 2023
Juraver-Geslin H, Devotta A, Saint-Jeannet JP.   +2 more
europepmc   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Natriuretic peptides and chronic heart failure in arterial hypertension patients

Кардиоваскулярная терапия и профилактика, 2007
The review is devoted to natriuretic peptides perspectives in left ventricular (LV) systolic and diastolic dysfunction assessment and LV hypertrophy diagnostics in arterial hypertension (AH) patients. The data describing possible antihypertensive therapy
Yu. A. Vasuyk, A. B. Khadzegova, S. V. Ivanova, I. M. Amirbegishvili, N. I. Gerasimova, E. N. Yushchuk, O. V. Krikunova, V. G. Bitsuev   +7 more
doaj  

Paper-based Microfluidic Immunoassay for Electrochemical Detection of B-type Natriuretic Peptide

, 2018
Yong Zheng, Zhen Huang, Jidong Zhang
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Additional file 1: of The association of the N-terminal pro-brain-type natriuretic peptide response to exercise with disease severity in therapy-naive pulmonary arterial hypertension: a cohort study

, 2018
J. Kutsch, Christian Faul, Wolfgang von Scheidt, Martin Schwaiblmair, Thomas M. Berghaus   +4 more
openalex   +1 more source